Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
75 studies found for:    Lung Transplant | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML);   MDS
Intervention: Device: CliniMACS CD34 selection system
22 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Conditions: Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions: Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
23 Recruiting Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
Conditions: Chronic Lymphocytic Leukemia;   CML (Chronic Myelogenous Leukemia);   MDS (Myelodysplastic Syndrome);   Acute Lymphoblastic Leukemia;   AML (Acute Myelogenous Leukemia)
Interventions: Biological: MVST;   Biological: MVSTr
24 Recruiting Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome
Conditions: Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions: Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
25 Recruiting Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Conditions: Graft vs Host Disease;   Healthy;   Lymphopenia
Intervention: Drug: G-CSF
26 Recruiting Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
Conditions: Graft vs Host Disease;   Hematologic Neoplasm
Intervention:
27 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune )
28 Recruiting Post‐Traumatic Stress Symptoms (PTSS) in Transplant Recipients
Conditions: Solid Organ Transplant Recipients;   Parent(s)/Guardian of Referenced Transplant Recipients
Intervention: Other: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
29 Recruiting Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Condition: Multiple Myeloma
Interventions: Procedure: Tumor Cell Collection;   Procedure: Autologous Stem Cell Transplant;   Drug: Melphalan;   Procedure: Leukapheresis;   Biological: Myeloma vaccine;   Drug: GM-CSF;   Drug: Lenalidomide
30 Recruiting Preventing Stem Cell Transplant Complications With a Blood Separator Machine
Conditions: MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention: Device: Graft Manipulation (CD34+ Selection)
31 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
Condition: Multiple Myeloma
Interventions: Procedure: Allogeneic HSCT;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Bortezomib;   Drug: Ixazomib;   Drug: Placebo
32 Recruiting AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: Chronic Graft vs Host Disease;   Chronic Graft-Versus-Host-Disease;   Bronchiolitis Obliterans Syndrome
Intervention: Drug: AZD9668
33 Not yet recruiting A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
Conditions: Hematologic Diseases;   Stem Cell Transplants
Intervention: Drug: PUL-042
34 Recruiting Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
35 Recruiting Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Conditions: Acute Leukemia;   Myelodysplasia
Interventions: Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
36 Recruiting Screening for Subjects to Participate in Studies of Blood Disorders
Conditions: Bone Marrow Transplant;   Sickle Cell Disease;   G-CSF
Intervention:
37 Recruiting Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Conditions: Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
Interventions: Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
38 Recruiting Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
Condition: ESRD
Intervention: Drug: Immune Tolerance
39 Recruiting Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
Condition: Immune Tolerance
Intervention: Device: Immune tolerance
40 Recruiting Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
Conditions: Stress;   Family Caregivers
Intervention: Other: Stress Reduction

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.